Callan Family Office LLC Makes New Investment in Repligen Corporation $RGEN

Callan Family Office LLC purchased a new position in shares of Repligen Corporation (NASDAQ:RGEN) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 4,712 shares of the biotechnology company’s stock, valued at approximately $643,000.

Several other institutional investors have also made changes to their positions in the company. Rachor Investment Advisory Services LLC acquired a new position in Repligen in the fourth quarter worth approximately $33,000. Measured Wealth Private Client Group LLC bought a new position in Repligen during the third quarter valued at approximately $29,000. Los Angeles Capital Management LLC acquired a new stake in Repligen in the fourth quarter valued at approximately $36,000. Farther Finance Advisors LLC lifted its stake in Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 128 shares during the last quarter. Finally, Itau Unibanco Holding S.A. grew its position in Repligen by 38.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 104 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

RGEN has been the topic of several analyst reports. Royal Bank Of Canada began coverage on shares of Repligen in a research note on Thursday, May 14th. They set an “outperform” rating and a $160.00 price target on the stock. Wells Fargo & Company lifted their price objective on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Zacks Research upgraded shares of Repligen from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. Weiss Ratings raised shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 13th. Finally, Wolfe Research initiated coverage on Repligen in a report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $166.43.

Insider Transactions at Repligen

In related news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.60% of the company’s stock.

Repligen Stock Up 0.0%

Shares of Repligen stock opened at $181.69 on Wednesday. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $188.73. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The stock has a 50 day moving average price of $149.17 and a two-hundred day moving average price of $132.22. The stock has a market capitalization of $10.25 billion, a P/E ratio of 248.89, a PEG ratio of 3.31 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same quarter last year, the firm posted $0.26 earnings per share. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities analysts expect that Repligen Corporation will post 2.06 earnings per share for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.